Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Shares Trade Near Recent Levels [Yahoo! Finance]
ACADIA Pharmaceuticals (ACAD) was upgraded by Bank of America Corporation from "neutral" to "buy". They now have a $29.00 price target on the stock.
Condor Software Raises $24 Million Series A Funding to Build the First Financial Intelligence Platform for Life Sciences [Yahoo! Finance]
ACADIA Pharmaceuticals Maps Key CNS Readouts: Remlifanserin ADP Data Due Aug–Oct, ACP-211 Next Year [Yahoo! Finance]